These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 22114915)
21. Transcriptomic concentration-response evaluation of valproic acid, cyproconazole, and hexaconazole in the neural embryonic stem cell test (ESTn). Theunissen PT; Robinson JF; Pennings JL; de Jong E; Claessen SM; Kleinjans JC; Piersma AH Toxicol Sci; 2012 Feb; 125(2):430-8. PubMed ID: 22045034 [TBL] [Abstract][Full Text] [Related]
22. Prediction of in vivo embryotoxic effect levels with a combination of in vitro studies and PBPK modelling. Verwei M; van Burgsteden JA; Krul CA; van de Sandt JJ; Freidig AP Toxicol Lett; 2006 Aug; 165(1):79-87. PubMed ID: 16517103 [TBL] [Abstract][Full Text] [Related]
23. Alternative methods to safety studies in experimental animals: role in the risk assessment of chemicals under the new European Chemicals Legislation (REACH). Lilienblum W; Dekant W; Foth H; Gebel T; Hengstler JG; Kahl R; Kramer PJ; Schweinfurth H; Wollin KM Arch Toxicol; 2008 Apr; 82(4):211-36. PubMed ID: 18322675 [TBL] [Abstract][Full Text] [Related]
24. Strategies and tools for preventing neurotoxicity: to test, to predict and how to do it. Llorens J; Li AA; Ceccatelli S; Suñol C Neurotoxicology; 2012 Aug; 33(4):796-804. PubMed ID: 22342764 [TBL] [Abstract][Full Text] [Related]
25. Development of a Combined In Vitro Physiologically Based Kinetic (PBK) and Monte Carlo Modelling Approach to Predict Interindividual Human Variation in Phenol-Induced Developmental Toxicity. Strikwold M; Spenkelink B; Woutersen RA; Rietjens IMCM; Punt A Toxicol Sci; 2017 Jun; 157(2):365-376. PubMed ID: 28498972 [TBL] [Abstract][Full Text] [Related]
26. Protein biomarkers for in vitro testing of toxicology. Schrattenholz A; Šoškić V; Schöpf R; Poznanović S; Klemm-Manns M; Groebe K Mutat Res; 2012 Aug; 746(2):113-23. PubMed ID: 22405942 [TBL] [Abstract][Full Text] [Related]
27. Strategies for the optimisation of in vivo experiments in accordance with the 3Rs philosophy. Madden JC; Hewitt M; Przybylak K; Vandebriel RJ; Piersma AH; Cronin MT Regul Toxicol Pharmacol; 2012 Jun; 63(1):140-54. PubMed ID: 22446816 [TBL] [Abstract][Full Text] [Related]
28. Zebrafish for drug toxicity screening: bridging the in vitro cell-based models and in vivo mammalian models. Sukardi H; Chng HT; Chan EC; Gong Z; Lam SH Expert Opin Drug Metab Toxicol; 2011 May; 7(5):579-89. PubMed ID: 21345150 [TBL] [Abstract][Full Text] [Related]
29. Tutorial on physiologically based kinetic modeling in molecular nutrition and food research. Rietjens IM; Louisse J; Punt A Mol Nutr Food Res; 2011 Jun; 55(6):941-56. PubMed ID: 21520492 [TBL] [Abstract][Full Text] [Related]
30. Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results. Yoon M; Campbell JL; Andersen ME; Clewell HJ Crit Rev Toxicol; 2012 Sep; 42(8):633-52. PubMed ID: 22667820 [TBL] [Abstract][Full Text] [Related]
31. Assessing toxicity of fine and nanoparticles: comparing in vitro measurements to in vivo pulmonary toxicity profiles. Sayes CM; Reed KL; Warheit DB Toxicol Sci; 2007 May; 97(1):163-80. PubMed ID: 17301066 [TBL] [Abstract][Full Text] [Related]
32. Integrating in vitro chemical transplacental passage into a generic PBK model: A QIVIVE approach. Fragki S; Hoogenveen R; van Oostrom C; Schwillens P; Piersma AH; Zeilmaker MJ Toxicology; 2022 Jan; 465():153060. PubMed ID: 34871708 [TBL] [Abstract][Full Text] [Related]
33. Evaluation of research activities and research needs to increase the impact and applicability of alternative testing strategies in risk assessment practice. Punt A; Schiffelers MJ; Jean Horbach G; van de Sandt JJ; Groothuis GM; Rietjens IM; Blaauboer BJ Regul Toxicol Pharmacol; 2011 Oct; 61(1):105-14. PubMed ID: 21782875 [TBL] [Abstract][Full Text] [Related]
34. Factors to consider in the use of stem cells for pharmaceutic drug development and for chemical safety assessment. Trosko JE; Chang CC Toxicology; 2010 Mar; 270(1):18-34. PubMed ID: 19948204 [TBL] [Abstract][Full Text] [Related]
35. Current and future needs for developmental toxicity testing. Makris SL; Kim JH; Ellis A; Faber W; Harrouk W; Lewis JM; Paule MG; Seed J; Tassinari M; Tyl R Birth Defects Res B Dev Reprod Toxicol; 2011 Oct; 92(5):384-94. PubMed ID: 21922641 [TBL] [Abstract][Full Text] [Related]
36. Quantitative in vitro-to-in vivo extrapolation in a high-throughput environment. Wetmore BA Toxicology; 2015 Jun; 332():94-101. PubMed ID: 24907440 [TBL] [Abstract][Full Text] [Related]
37. Stem cell models for drug discovery and toxicology studies. Liu W; Deng Y; Liu Y; Gong W; Deng W J Biochem Mol Toxicol; 2013 Jan; 27(1):17-27. PubMed ID: 23293059 [TBL] [Abstract][Full Text] [Related]
38. Human embryonic stem cell proliferation and differentiation as parameters to evaluate developmental toxicity. Pal R; Mamidi MK; Das AK; Bhonde R J Cell Physiol; 2011 Jun; 226(6):1583-95. PubMed ID: 20945368 [TBL] [Abstract][Full Text] [Related]
39. Use of physiologically based kinetic modelling-facilitated reverse dosimetry to convert in vitro cytotoxicity data to predicted in vivo liver toxicity of lasiocarpine and riddelliine in rat. Chen L; Ning J; Louisse J; Wesseling S; Rietjens IMCM Food Chem Toxicol; 2018 Jun; 116(Pt B):216-226. PubMed ID: 29634986 [TBL] [Abstract][Full Text] [Related]
40. Assessment of the Embryonic Stem Cell Test and application and use in the pharmaceutical industry. Paquette JA; Kumpf SW; Streck RD; Thomson JJ; Chapin RE; Stedman DB Birth Defects Res B Dev Reprod Toxicol; 2008 Apr; 83(2):104-11. PubMed ID: 18361453 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]